Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
1.
J Invasive Cardiol ; 35(3): E128-E135, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36645333

RESUMEN

BACKGROUND: Severe coronary artery calcification (CAC) remains challenging during percutaneous coronary intervention (PCI) and often requires 1 or more advanced calcium modification tools. OBJECTIVES: We describe the combination use of rotational (RA) or orbital atherectomy (OA), with intravascular lithotripsy (IVL), termed rotatripsy and orbital-tripsy, respectively, for modifying CAC prior to stent implantation during PCI. METHODS: We performed a retrospective analysis of patients treated with rotatripsy or orbital-tripsy at our center between July 2019 and March 2022. The primary efficacy endpoint was procedural success (successful stent implantation, <30% residual stenosis visually, Thrombolysis in Myocardial Infarction 3 flow; absence of types C to F dissection/perforation or loss of side branch ≥2.0mm visually) without in-hospital major adverse cardiovascular event (MACE, defined as cardiovascular death, myocardial infarction [MI], target-vessel revascularization). RESULTS: A total of 25 patients (14 rotatripsy and 11 orbital-tripsy) were included in our study. The mean age was 72.2 ± 7.6 years and 76% were men. PCI was guided by intravascular imaging in 24 patients (96%). All cases were treated with either RA or OA before utilization of IVL. Procedural success was achieved in 22 cases (88%) with 1 sidebranch loss without periprocedural MI (4%) and 2 in-patient deaths (8%) unrelated to the procedure (1 intracerebral hemorrhage and 1 cardiac arrest). CONCLUSION: We describe efficacious use of both rotatripsy and orbital-tripsy to modify severe CAC during PCI in a real-world setting. Intravascular imaging can guide appropriate use of these devices to complement each other to modify severe CAC to achieve optimal outcomes.


Asunto(s)
Aterectomía Coronaria , Enfermedad de la Arteria Coronaria , Litotricia , Infarto del Miocardio , Intervención Coronaria Percutánea , Calcificación Vascular , Masculino , Humanos , Persona de Mediana Edad , Anciano , Femenino , Intervención Coronaria Percutánea/métodos , Aterectomía Coronaria/métodos , Calcio , Estudios Retrospectivos , Vasos Coronarios/diagnóstico por imagen , Vasos Coronarios/cirugía , Resultado del Tratamiento , Enfermedad de la Arteria Coronaria/diagnóstico , Enfermedad de la Arteria Coronaria/cirugía , Infarto del Miocardio/etiología , Aterectomía , Calcificación Vascular/diagnóstico , Calcificación Vascular/cirugía , Angiografía Coronaria/métodos
2.
J Clin Med ; 10(10)2021 May 17.
Artículo en Inglés | MEDLINE | ID: mdl-34067605

RESUMEN

Left ventricular hypertrophy (LVH) caused by cardiac variant Fabry disease (FD) is typically late-onset and may mimic LVH caused by abnormal loading conditions. We aimed to determine the prevalence of FD in a non-selective patient population of everyday practice presenting with LVH, including those with hypertension and valve disease. We measured plasma alpha-galactosidase A activity using dried blood spot tests in 499 (age = 66 ± 13 years; 336 men) Hong Kong Chinese patients with LVH defined as maximal LV septal/posterior wall thickness ≥13 mm on echocardiography. Patients with low enzyme activity underwent mutation analysis of the GLA gene. Eight (age = 53-74 years; all men) unrelated patients (1.6%) had low plasma alpha-galactosidase A activity (0.57 ± 0.27 µmol/L wb/hr) and all were confirmed to have the GLA IVS4 + 919G > A mutation. FD patients presented with heart failure (n = 5), heart block (n = 2), ventricular tachycardia (n = 1), chest pain (n = 3), and/or murmur (n = 1). Uncontrolled hypertension (n = 4) and/or severe mitral/aortic valve pathology (n = 2) were frequent. Ethnic subgroups included Teochew (n = 5), Canton (n = 2), and Wenzhou (n = 1). Endomyocardial biopsy (n = 6) revealed hypertrophic myocytes with vacuolization and dense lamellar bodies. Late-onset IVS4 + 919G > A FD is prevalent among Chinese LVH patients, and should be considered as a cause of LVH in adult patients even when hypertension and/or valve pathology are present.

3.
PLoS One ; 15(9): e0239675, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32987398

RESUMEN

Fabry Disease (FD) is a systemic disorder that can result in cardiovascular, renal, and neurovascular disease leading to reduced life expectancy. FD should be considered in the differential of all patients with unexplained left ventricular hypertrophy (LVH). We therefore performed a prospective screening study in Edmonton and Hong Kong using Dried Blood Spot (DBS) testing on patients with undiagnosed LVH. Participants found to have unexplained LVH on echocardiography were invited to participate and subsequently subjected to DBS testing. DBS testing was used to measure α-galactosidase (α-GAL) enzyme activity and for mutation analysis of the α-galactosidase (GLA) gene, both of which are required to make a diagnosis of FD. DBS testing was performed as a screening tool on patients (n = 266) in Edmonton and Hong Kong, allowing for detection of five patients with FD (2% prevalence of FD) and one patient with hydroxychloroquine-induced phenocopy. Left ventricular mass index (LVMI) by GLA genotype showed a higher LVMI in patients with IVS4 + 919G > A mutations compared to those without the mutation. Two patients were initiated on ERT and hydroxychloroquine was discontinued in the patient with a phenocopy of FD. Overall, we detected FD in 2% of our screening cohort using DBS testing as an effective and easy to administer screening tool in patients with unexplained LVH. Utilizing DBS testing to screen for FD in patients with otherwise undiagnosed LVH is clinically important due to the availability of effective therapies and the value of cascade screening in extended families.


Asunto(s)
Enfermedad de Fabry/diagnóstico , Enfermedad de Fabry/enzimología , Hipertrofia Ventricular Izquierda/diagnóstico , Hipertrofia Ventricular Izquierda/enzimología , Tamizaje Masivo/métodos , alfa-Galactosidasa/genética , Adulto , Anciano , Anciano de 80 o más Años , Análisis Mutacional de ADN , Diagnóstico Diferencial , Pruebas con Sangre Seca , Ecocardiografía , Enfermedad de Fabry/epidemiología , Femenino , Genotipo , Hong Kong/epidemiología , Humanos , Hipertrofia Ventricular Izquierda/epidemiología , Masculino , Persona de Mediana Edad , Mutación , Fenotipo , Estudios Prospectivos
4.
J Invasive Cardiol ; 32(7): E190, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32610273

RESUMEN

Venography alone may underestimate the extent of common iliac vein compression in May-Thurner syndrome. Peripheral intravascular ultrasound is mandatory to better assess common iliac vein compression.


Asunto(s)
Síndrome de May-Thurner , Rabdomiólisis , Trombosis de la Vena , Humanos , Vena Ilíaca/diagnóstico por imagen , Síndrome de May-Thurner/complicaciones , Síndrome de May-Thurner/diagnóstico , Rabdomiólisis/diagnóstico , Rabdomiólisis/etiología , Vena Cava Inferior , Trombosis de la Vena/etiología
8.
Clin Med (Lond) ; 20(1): 107-109, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31941743

RESUMEN

Ion-exchange resins, sodium or calcium polystyrene sulfonate, are commonly used medications for management of hyperkalaemia. However, the drug can be associated with serious bowel injury. We report a case of a renal transplant recipient who developed duodenal ulcer perforation secondary to the use of calcium polystyrene sulfonate. Characteristic eosinophilic non-polarisable rhomboid shaped crystals were evident in the affected area of ulceration on histologic examination in addition to features of cytomegalovirus inclusions. We also hypothesised that gastroparesis secondary to autonomic dysfunction could have led to prolonged luminal contact time with polystyrene, further predisposing to bowel injury.


Asunto(s)
Úlcera Duodenal , Hiperpotasemia , Úlcera Duodenal/inducido químicamente , Humanos , Hiperpotasemia/inducido químicamente , Poliestirenos/efectos adversos , Sodio
17.
JACC Clin Electrophysiol ; 4(9): 1214-1223, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-30236396

RESUMEN

OBJECTIVES: This study aimed to examine the relationship between chronic coronary artery total occlusion (CTO) status and the occurrence of ventricular tachycardia (VT)/ventricular fibrillation (VF) or appropriate implantable cardioverter-defibrillator (ICD) therapy. BACKGROUND: CTO is a significant problem in patients with ischemic heart disease. However, the extent to which it predisposes affected individuals to VT/VF and whether these arrhythmic events could be prevented by revascularization are unclear. Therefore, a systematic review and meta-analysis were conducted to examine the relationship between CTO status and the occurrence of VT/VF or appropriate ICD therapy. METHODS: PubMed and Embase databases were searched until November 16, 2017, identifying 137 studies. RESULTS: Seventeen studies involving 54,594 subjects (mean age, 61 ± 21 years of age, 81% male) with a mean follow-up of 43 ± 31 months were included. The presence of CTO was associated with higher risk of VT/VF or appropriate ICD therapy (adjusted hazard ratio [aHR]: 1.99; 95% confidence interval (CI): 1.53 to 2.59; p < 0.0001, I2 = 3%) but not in cardiac mortality (aHR: 2.59; 95% CI: 0.64 to 10.59; p = 0.18, I2 = 86%) or in all-cause mortality (aHR: 1.70; 95% CI: 0.84 to 3.46; p = 0.14; I2 = 64%). Compared to patients with non-infarct-related CTOs, those with infarct-related CTOs have a higher risk of VT/VF or appropriate ICD therapy (aHR: 2.47; 95% CI: 1.76 to 3.46; p < 0.0001; I2 = 14%), cardiac mortality (aHR: 2.73; 95% CI: 1.02 to 7.30; p < 0.05; I2 = 79%) and higher all-cause mortality (aHR: 1.69; 95% CI: 1.19 to 2.40; p < 0.01; I2 = 40%). Nonrevascularization of CTOs tended to be associated with an increased risk of all-cause mortality compared to successful revascularization (unadjusted HR: 1.52; 95% CI: 0.96 to 2.43; p = 0.08; I2 = 76). CONCLUSIONS: CTOs, especially infarct-related, are associated with high risk of VT/VF or appropriate ICD therapy and mortality. ICD implantation could be beneficial. However, it is not clear that revascularization has an impact on the outcome of patients with CTOs.


Asunto(s)
Oclusión Coronaria , Taquicardia Ventricular , Fibrilación Ventricular , Adulto , Anciano , Anciano de 80 o más Años , Oclusión Coronaria/complicaciones , Oclusión Coronaria/epidemiología , Oclusión Coronaria/mortalidad , Desfibriladores Implantables , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio , Taquicardia Ventricular/complicaciones , Taquicardia Ventricular/epidemiología , Taquicardia Ventricular/mortalidad , Fibrilación Ventricular/complicaciones , Fibrilación Ventricular/epidemiología , Fibrilación Ventricular/mortalidad
18.
J Invasive Cardiol ; 30(7): E57-E58, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29958179
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...